|
1
|
Turk V, Stoka V and Turk D: Cystatins:
Biochemical and structural properties, and medical relevance. Front
Biosci. 13:5406–5420. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Žerovnik E: Putative alternative functions
of human stefin B (cystatin B): Binding to amyloid-beta, membranes,
and copper. J Mol Recognit. 30:302017. View
Article : Google Scholar
|
|
3
|
Wang X, Gui L, Zhang Y, Zhang J, Shi J and
Xu G: Cystatin B is a progression marker of human epithelial
ovarian tumors mediated by the TGF-β signaling pathway. Int J
Oncol. 44:1099–1106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maher K, Jerič Kokelj B, Butinar M,
Mikhaylov G, Manček-Keber M, Stoka V, Vasiljeva O, Turk B,
Grigoryev SA and Kopitar-Jerala N: A role for stefin B (cystatin B)
in inflammation and endotoxemia. J Biol Chem. 289:31736–31750.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lalioti MD, Scott HS, Buresi C, Rossier C,
Bottani A, Morris MA, Malafosse A and Antonarakis SE: Dodecamer
repeat expansion in cystatin B gene in progressive myoclonus
epilepsy. Nature. 386:847–851. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gashenko EA, Lebedeva VA, Brak IV,
Tsykalenko EA, Vinokurova GV and Korolenko TA: Evaluation of serum
proca-thepsin B, cystatin B and cystatin C as possible biomarkers
of ovarian cancer. Int J Circumpolar Health. 72:212152013.
View Article : Google Scholar
|
|
9
|
Feldman AS, Banyard J, Wu CL, McDougal WS
and Zetter BR: Cystatin B as a tissue and urinary biomarker of
bladder cancer recurrence and disease progression. Clin Cancer Res.
15:1024–1031. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee MJ, Yu GR, Park SH, Cho BH, Ahn JS,
Park HJ, Song EY and Kim DG: Identification of cystatin B as a
potential serum marker in hepatocellular carcinoma. Clin Cancer
Res. 14:1080–1089. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shiraishi T, Mori M, Tanaka S, Sugimachi K
and Akiyoshi T: Identification of cystatin B in human esophageal
carcinoma, using differential displays in which the gene expression
is related to lymph-node metastasis. Int J Cancer. 79:175–178.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Treiber T, Treiber N and Meister G:
Regulation of microRNA biogenesis and its crosstalk with other
cellular pathways. Nat Rev Mol Cell Biol. 20:5–20. 2019. View Article : Google Scholar
|
|
13
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van Kouwenhove M, Kedde M and Agami R:
MicroRNA regulation by RNA-binding proteins and its implications
for cancer. Nat Rev Cancer. 11:644–656. 2011. View Article : Google Scholar
|
|
16
|
Zhang L, Nadeem L, Connor K and Xu G:
Mechanisms and therapeutic targets of microRNA-associated
chemoresistance in epithelial ovarian cancer. Curr Cancer Drug
Targets. 16:429–441. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Behbahani GD, Ghahhari NM, Javidi MA,
Molan AF, Feizi N and Babashah S: MicroRNA-mediated
post-transcriptional regulation of epithelial to mesenchymal
transition in cancer. Pathol Oncol Res. 23:1–12. 2017. View Article : Google Scholar
|
|
18
|
Schetter AJ, Heegaard NH and Harris CC:
Inflammation and cancer: Interweaving microRNA, free radical,
cytokine and p53 pathways. Carcinogenesis. 31:37–49. 2010.
View Article : Google Scholar
|
|
19
|
Ottley E and Gold E: microRNA and
non-canonical TGF-β signalling: Implications for prostate cancer
therapy. Crit Rev Oncol Hematol. 92:49–60. 2014. View Article : Google Scholar
|
|
20
|
Shi Y and Massagué J: Mechanisms of
TGF-beta signaling from cell membrane to the nucleus. Cell.
113:685–700. 2003. View Article : Google Scholar
|
|
21
|
Attisano L and Wrana JL: Signal
transduction by the TGF-beta superfamily. Science. 296:1646–1647.
2002. View Article : Google Scholar
|
|
22
|
Schmierer B and Hill CS: TGFbeta-SMAD
signal transduction: Molecular specificity and functional
flexibility. Nat Rev Mol Cell Biol. 8:970–982. 2007. View Article : Google Scholar
|
|
23
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun W, Gui L, Zuo X, Zhang L, Zhou D, Duan
X, Ren W and Xu G: Human epithelial-type ovarian tumour marker
beta-2-micro-globulin is regulated by the TGF-β signaling pathway.
J Transl Med. 14:752016. View Article : Google Scholar
|
|
25
|
Matsumoto T, Yokoi A, Hashimura M, Oguri
Y, Akiya M and Saegusa M: TGF-β-mediated LEFTY/Akt/GSK-3β/Snail
axis modulates epithelial-mesenchymal transition and cancer stem
cell properties in ovarian clear cell carcinomas. Mol Carcinog.
57:957–967. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu KH, Patterson AP, Wang L, Marquez RT,
Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I,
et al: Selection of potential markers for epithelial ovarian cancer
with gene expression arrays and recursive descent partition
analysis. Clin Cancer Res. 10:3291–3300. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bonome T, Levine DA, Shih J, Randonovich
M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC,
Boyd J, et al: A gene signature predicting for survival in
suboptimally debulked patients with ovarian cancer. Cancer Res.
68:5478–5486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) μethod. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
29
|
Takaya A, Peng WX, Ishino K, Kudo M,
Yamamoto T, Wada R, Takeshita T and Naito Z: Cystatin B as a
potential diagnostic biomarker in ovarian clear cell carcinoma. Int
J Oncol. 46:1573–1581. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin YY, Chen ZW, Lin ZP, Lin LB, Yang XM,
Xu LY and Xie Q: Tissue Levels of Stefin A and Stefin B in
Hepatocellular Carcinoma. Anat Rec (Hoboken). 299:428–438. 2016.
View Article : Google Scholar
|
|
31
|
Kos J, Krasovec M, Cimerman N, Nielsen HJ,
Christensen IJ and Brünner N: Cysteine proteinase inhibitors stefin
A, stefin B, and cystatin C in sera from patients with colorectal
cancer: Relation to prognosis. Clin Cancer Res. 6:505–511.
2000.PubMed/NCBI
|
|
32
|
Butinar M, Prebanda MT, Rajkovic J, Jerič
B, Stoka V, Peters C, Reinheckel T, Krüger A, Turk V, Turk B, et
al: Stefin B deficiency reduces tumor growth via sensitization of
tumor cells to oxidative stress in a breast cancer model. Oncogene.
33:3392–3400. 2014. View Article : Google Scholar
|
|
33
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng CJ, Bahal R, Babar IA, Pincus Z,
Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM,
et al: MicroRNA silencing for cancer therapy targeted to the tumour
microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar
|
|
35
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
He Z, Yi J, Liu X, Chen J, Han S, Jin L,
Chen L and Song H: MiR-143-3p functions as a tumor suppressor by
regulating cell proliferation, invasion and epithelial-mesenchymal
transition by targeting QKI-5 in esophageal squamous cell
carcinoma. Mol Cancer. 15:512016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhai L, Ma C, Li W, Yang S and Liu Z:
miR-143 suppresses epithelial-mesenchymal transition and inhibits
tumor growth of breast cancer through down-regulation of ERK5. Mol
Carcinog. 55:1990–2000. 2016. View Article : Google Scholar
|
|
38
|
Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z,
Li P, Zhang W, Wu H, Feng N, et al: miR-143 decreases prostate
cancer cells proliferation and migration and enhances their
sensitivity to docetaxel through suppression of KRAS. Mol Cell
Biochem. 350:207–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Song T, Zhang X, Wang C, Wu Y, Dong J, Gao
J, Cai W and Hong B: Expression of miR-143 reduces growth and
migration of human bladder carcinoma cells by targeting
cyclooxygenase-2. Asian Pac J Cancer Prev. 12:929–933. 2011.
|
|
40
|
Shi H, Shen H, Xu J, Zhao S, Yao S and
Jiang N: MiR-143-3p suppresses the progression of ovarian cancer.
Am J Transl Res. 10:866–874. 2018.
|
|
41
|
Long X and Miano JM: Transforming growth
factor-beta1 (TGF-beta1) utilizes distinct pathways for the
transcriptional activation of microRNA 143/145 in human coronary
artery smooth muscle cells. J Biol Chem. 286:30119–30129. 2011.
View Article : Google Scholar
|
|
42
|
Davis-Dusenbery BN, Chan MC, Reno KE,
Weisman AS, Layne MD, Lagna G and Hata A: down-regulation of
Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for
modulation of vascular smooth muscle cell phenotype by transforming
growth factor-beta and bone morphogenetic protein 4. J Biol Chem.
286:28097–28110. 2011. View Article : Google Scholar : PubMed/NCBI
|
